Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1907250rdf:typepubmed:Citationlld:pubmed
pubmed-article:1907250lifeskim:mentionsumls-concept:C0011854lld:lifeskim
pubmed-article:1907250lifeskim:mentionsumls-concept:C0011881lld:lifeskim
pubmed-article:1907250lifeskim:mentionsumls-concept:C0042971lld:lifeskim
pubmed-article:1907250lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:1907250pubmed:issue8lld:pubmed
pubmed-article:1907250pubmed:dateCreated1991-9-4lld:pubmed
pubmed-article:1907250pubmed:abstractTextWe tested the hypothesis that dysfunction of vascular endothelium, indicated by an increase in plasma level of von Willebrand factor (vWF), is present in patients with insulin-dependent diabetes mellitus (IDDM) who develop diabetic nephropathy (DN). DN was classified as absent (urinary albumin excretion [UAE] rate less than 15 microgram/min), incipient (UAE rate 15-200 micrograms/min), or clinical (UAE rate greater than 200 micrograms/min). We followed a cohort of 59 patients for a median of 3 yr. At baseline, 52 patients had no DN, 6 had incipient DN, and 1 had clinical DN. At follow-up, 38 patients had no DN (group 1). Incipient DN had developed in 14 patients and worsened in 3 patients. Clinical DN had worsened in 1 patient. Together, these 18 patients comprised group 2. A decrease in UAE was observed in the remaining three patients with incipient DN at baseline (group 3). In group 1, vWF--measured by immunoelectrophoresis and expressed as a percentage of normal--increased slightly (median 10%, range -43 to 145, P = 0.009). In group 2, vWF increased in all patients (median 80%, range 14 to 206 [corrected], P = 0.0002 vs. baseline and group 1). In group 3, vWF decreased (median -19%, range -44 to -18). After correction for possible confounders, i.e., age, varying duration of follow-up, and initial level of vWF, the difference in vWF change between groups 1 and 2 remained significant (P = 0.009). Poor glycemic control at baseline, estimated by glycosylated hemoglobin, was a significant predictor of increases in vWF in both group 1 and groups 1 and 2 combined.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1907250pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:languageenglld:pubmed
pubmed-article:1907250pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1907250pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1907250pubmed:statusMEDLINElld:pubmed
pubmed-article:1907250pubmed:monthAuglld:pubmed
pubmed-article:1907250pubmed:issn0012-1797lld:pubmed
pubmed-article:1907250pubmed:authorpubmed-author:HackengW HWHlld:pubmed
pubmed-article:1907250pubmed:authorpubmed-author:Den...lld:pubmed
pubmed-article:1907250pubmed:authorpubmed-author:MulderP GPGlld:pubmed
pubmed-article:1907250pubmed:authorpubmed-author:StehouwerC...lld:pubmed
pubmed-article:1907250pubmed:authorpubmed-author:StroesE SESlld:pubmed
pubmed-article:1907250pubmed:issnTypePrintlld:pubmed
pubmed-article:1907250pubmed:volume40lld:pubmed
pubmed-article:1907250pubmed:ownerNLMlld:pubmed
pubmed-article:1907250pubmed:authorsCompleteYlld:pubmed
pubmed-article:1907250pubmed:pagination971-6lld:pubmed
pubmed-article:1907250pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:meshHeadingpubmed-meshheading:1907250-...lld:pubmed
pubmed-article:1907250pubmed:year1991lld:pubmed
pubmed-article:1907250pubmed:articleTitlevon Willebrand factor and development of diabetic nephropathy in IDDM.lld:pubmed
pubmed-article:1907250pubmed:affiliationDepartment of Internal Medicine, Bergweg Municipal Hospital, Rotterdam, Netherlands.lld:pubmed
pubmed-article:1907250pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1907250lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1907250lld:pubmed